In vivo investigation of CD133 as a putative marker of cancer stem cells in hep-2 cell line

Head and Neck

Volumn 31, Issue 1, 2009, Pages 94-101

  Wei, Xu Dong ^a   Zhou, Liang ^a   Cheng, Lei ^a   Tian, Jie ^a   Jiang, Jack J ^b   MacCallum, Julia ^b  

^a FUDAN UNIVERSITY   (China)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Cancer stem cells; Hep 2 cell line

Indexed keywords

CD133 ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CANCER STEM CELL; CELL LINE; CELL SELECTION; CONTROLLED STUDY; FLOW CYTOMETRY; HEP 2 CELL; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNOMAGNETIC SEPARATION; IN VITRO STUDY; IN VIVO STUDY; LARYNX TUMOR; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANTIGENS, CD; CELL CYCLE; CELL LINE, TUMOR; FLOW CYTOMETRY; GLYCOPROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOMAGNETIC SEPARATION; LARYNGEAL NEOPLASMS; NEOPLASTIC STEM CELLS; PEPTIDES;

EID: 58149508462     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.20935     Document Type: Article

References (33)

1. Bonnet D, Dick J. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730-737.
2. Taipale J, Beachy PA. The Hedgehog and Wnt signalling pathways in cancer. Nature 2001;411:349-354.
3. Norman J, Collins A. A tumour stem cell hypothesis for the origins of prostate cancer. BJU Int 2005;96:1219-1223.
4. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105-111.
5. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003;100: 3983-3988.
6. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003;63:5821-5828.
7. Collins AT, Berry PA, Hyde C, et al. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005;65:10946-10951.
8. Kim CFB, El J, Woolfenden AE, et al. Identification of bronchioalvelar stem cell in normal lung and lung cancer. Cell 2005;121:823-835.
9. Heidt DG, Li C, Mollenberg N, Clarke, et al. Identification of pancreatic cancer stem cells. J Surg Res 2006;2: 194-195.
10. Seigel GM, Campbell LM, Narayan M, et al. Cancer stem cell characteristies in retinoblastoma. Mol Vis 2005; 11:729-737.
11. Fang D, Nguyen TK, Leishear K, et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 2005;65:9328-9337.
12. Yin AH, Miraglia S, Zanjani ED, et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997;90:5002-5012.
13. Peichev M, Naiyer AJ, Pereira D, et al. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 2000;95:952-958.
14. Uchida N, Buck D W, He D, et al. Direct isolation of human central nervous system stem cells. Proc Natl Acad Sci U S A 2000;97:14720-14725.
15. Corbeil D, Roper K, Hellwig A, et al. The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions. J Biol Chem 2000;275:5512-5520.
16. Weigmann A, Corbei D, Hellwig A, et al. Prominin, a novemicrovilli- specific polytopic membrane protein of the apical surface of epithelial cells, is targeted to plasma-lemmal protrusions of non-epithelial cells. Proc Natl Acad Sci U S A 1997;94:12425-12430.
17. Collins A, Hyde K, Berry KP, et al. α2(31HI/CD133+ prostate cancer stem cell from human tumors are highly tumorigenic in vivo. Eur Urol Suppl 2006;5:790.
18. Richardson GD, Robson CN, Lang SH, et al. CD133, a novel marker for human prostatic epithelial stem cells.J Cell Sci 2004;117:3539-3545.
19. Collins AT, Berry PA, Hyde C, et al. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005;65:10946-10951.
20. Rizzo S, Attard G, Hudson DL. Prostate epithelial stem cells. Cell Prolif 2005;38:363-374.
21. Pilkington GJ. Cancer stem cells in the mammalian central nervous system. Cell Prolif 2005;38:423-433.
22. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature 2004;432: 396-401.
23. Dirks PB. Brain tumor stem cell. Biol Blood Marrow Transpl 2005;11:12-13.
24. Al-Hajj1 M, Clarke MF. Self-renewal and solid tumor stem cells. Oncogene 2004;23:7274-7282.
25. Pilkington GJ. Cancer stem cells in the mammalian central nervous system. Cell Prolif 2005;38:423-433.
26. Nakano I, Kornblum H. Brain tumor stem cells. Pediatr Res 2006;59:54-58.
27. Collins AT, Maitland NJ. Prostate cancer stem cells. Eur J Cancer 2006;42:1213-1218.
28. Kondo T, Setoguchi T, Taga T. Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci U S A 2004;101:781-786.
29. Zhou L, Wei X, Cheng L, Tian J, Jiang JJ. CD133, one of the markers of cancer stem cells in Hep-2 cell line. Laryngoscope 2007;117:455-460.
30. Lloyd DR, Holmes P, Jackson, et al. Relationship between cell size, cell cycle and specific recombinant protein productivity. Cytotechnology 2000;34:59-70.
31. Bosma GC, Custer RP, Bosma MJ. A severe combined immunodeficiency mutation in the mouse. Nature 1983; 301:527-530.
32. Al-Hajj M, Becker MW, Wicha M, Weissman I, Clarke MF. Therapeutic implication of cancer stem cells. Curr Opin Genet Dev. 2004;14:43-47.
33. Prince ME, Sivanandan R, Kaczorowski A, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. PNAS 2007;104:973-978.